相关实验视频
Updated: Jun 23, 2026
10:33
Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
20.9K
在乳化剂之间改进了基于酸盐的分散剂和离子交联的毫米大小囊.
Yulu Zheng1,2, Ye Zi2, Cuiping Shi1
1Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
NPJ science of food
|June 27, 2023
概括
混合Tween表面活性剂与酸盐改善了鱼油封装稳定性和氧化抵抗力. 特定的Tween特性影响了负载,效率和体外消化,增强了鱼油.
科学领域:
- 食品科学与技术 食品科学与技术
- 材料科学 材料科学 材料科学
- 生物化学 生物化学
背景情况:
- 基于酸盐的封装对于稳定鱼油等油来说至关重要.
- 表面活性剂可以改变这些封装系统的特性.
- 了解表面活性剂相互作用是优化石油输送和生物可用性的关键.
研究的目的:
- 调查Tween系列表面活性剂 (20,40,60,80) 对鱼油封装的酸盐系统的影响.
- 评估Tween混合如何影响乳液特性,囊特性和鱼油稳定性.
- 为了确定Tween结构对封装效率和体外消化的影响.
主要方法:
- 用鱼油制备藻酸盐分散剂和藻酸盐囊.
- 纳入和评估Tween 20,40,60和80作为混合剂.
- 分析奶油的稳定性,颗粒大小,含水量和表面形态.
- 评估鱼油载荷能力,封装效率,氧化稳定性和体外释放.
主要成果:
- 与Span 80相比,Tween 80表现出优越的乳化特性.
- 所有的Tween系列比单独的阿尔金酸盐增强了奶油的稳定性.
- 囊大小保持不变,但随着Tween的添加,水含量下降.
- 鱼油加载和封装效率因Tween的水友和脂肪酸成分而异.
- 在混合之间改善了鱼油的氧化稳定性.
- 与和脂肪酸相关的表面活性剂在消化过程中增加了自由脂肪酸的释放.
结论:
- 介于系列间的表面活性剂有效地提高了鱼油封装的酸盐的稳定性和氧化抵抗力.
- Tween表面活性剂的特定化学结构决定了它们在封装中的性能,并影响了鱼油的生物可用性.
- 这项研究提供了新的加工策略,通过优化藻酸盐封装来提高鱼油的生物有效性.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...